Rallybio

Today is World HPP Day! It’s our chance to shine a light on this rare disease. For those who don’t know, hypophosphatasia is caused by a mutation in the ALPL (TNSALP) gene. Low alkaline phosphatase (ALP) levels on a standard blood panel can be a sign of HPP. As research advances, we're uncovering the broader implications of HPP and how it goes beyond bones and teeth. Our new app, myHPP, is already helping us to better understand symptoms that will drive future research initiatives. Together we can change the trajectory of HPP! Help support our mission by donating $15 to celebrate our 15th anniversary. Visit our World HPP Day page to donate. https://lnkd.in/eMjrm-Ke

FNAIT is officially on notice 📣 today, as we’ve announced the CTA approval of our lead program, RLYB212, to move into a Phase 2 trial in pregnant women at higher risk of alloimmunization and FNAIT.    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare immune disorder in which a mother's body develops an antigen response against her baby's platelets and can cause uncontrolled bleeding or death in mothers, fetuses and newborns.     More than 30,000 pregnancies are at risk every year, and this trial is the next step in advancing RLYB212 aimed at preventing maternal alloimmunization and FNAIT.    Learn more about what's coming up next and how we're working towards the prevention of this #raredisease for pregnant women everywhere:

🧑🔬 Amanda Hayward, Head of Global Business Development presented our research, in partnership with HealthLumen, on quantifying the proportion of women at risk of an FNAIT pregnancy in diverse populations in the United States at NORD today.     The study reveals key findings on fetal/neonatal alloimmune thrombocytopenia (FNAIT) risk across diverse ancestries for the first time.     ˃˃ Using genetic data, researchers found that nearly 20,000 pregnancies in the U.S. are at higher risk for FNAIT each year—far more than previously estimated.    ˃˃ The study highlights that non-White populations also carry significant FNAIT risk, challenging past assumptions.    ˃˃ These findings make a compelling case for universal screening of pregnant women for FNAIT risk, regardless of race or ethnicity, and we’re proud to play a part in advocating for a future where this is the norm.     #HealthEquity #FNAIT #MaternalHealth #NORD #NORD24  

🗣️NORD Breakthrough Summit attendees – join our co-founder Martin Mackay, Ph.D., as he discusses “How Investors See the Rare Space NOW” today at 11:20 a.m. ET! #Raredisease #NORD24    

Attending NORD Breakthrough Summit in D.C. next week? Look out for our co-founder, Martin Mackay, Ph.D., discussing “How Investors See the Rare Space NOW” on Tuesday, October 22nd, at 11:20 a.m. ET        Let us know if we’ll see you there! #Raredisease #NORD24

A recent study examined delivery hospitalizations from 2016-2019, uncovering significant racial and ethnic disparities in severe maternal morbidity (SMM) across various U.S. communities. Examples of SMM include: heart attack, heart failure, eclampsia, sepsis/blood infection, and hysterectomy.  Key findings: 👉 Non-Hispanic Black women face notably higher risks of SMM, regardless of their community's income level or location. 👉 In urban areas, black women are 88% more likely to experience SMM compared to white women. 👉 Disparities persist even in the highest-income communities, where black women have over twice the odds of SMM compared to their White counterparts. These results highlight the urgent need for tailored healthcare strategies to address systemic inequities in maternal health.  https://lnkd.in/gy7HEZNY As we continue working to improve maternal and fetal health, you can learn more about our efforts to address disparities in another critical area: fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in diverse ancestries. Read more here: https://lnkd.in/gKce2vJz #MaternalHealth #HealthEquity #PublicHealth #HealthcareResearch

We're honored to present our latest data with our partners Exscientia and Millán Lab, validating ENPP1 inhibition as a therapeutic approach to late-onset HPP. More to come later this year on our differentiated ENPP1 inhibitor, and how we're coming together to address the significant unmet patient need in this space.

📣 Exciting news from Rallybio! Today at #ASBMR2024 with our partners Exscientia and Millán Lab, we debuted promising nonclinical data supporting ENPP1 inhibition as a therapeutic approach for hypophosphatasia (HPP) for the first time. Thanks to Dr. José Luis Millán for presenting these findings - With the significant unmet patient need, especially among adults, our findings bring hope for a potential new treatment that could improve the lives of those battling this devastating rare disease.     We're encouraged to see this data as we continue to work with Exscientia on an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address the unmet need in patients with HPP. We expect to have more to share on our inhibitor development candidate later this year - for now, download our poster here to take a closer look: https://lnkd.in/eesRGgsr   #RareDisease #HPP #ASBMR2024 

 We are proud to announce that Rallybio is a 2024 Fierce 50 report honoree. 👏 The Fierce 50 recognizes companies and individuals who have demonstrated a steadfast commitment to innovation, equity, and improving lives. Being named to this year’s list underscores our relentless focus on tackling FNAIT and other rare diseases that affect those most at risk. Read more about this year’s Innovation honorees here: https://lnkd.in/e7RE5ZZg 

🗣️ For those attending the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference: Rallybio’s Co-founder and CEO Stephen Uden will be presenting a corporate overview on Tuesday, 9/10 at 11:00 a.m. ET. Don’t miss it! Not attending the 26th? No problem! Head to our website's Events and Presentations section to listen to the live webcast the next 30 days: https://lnkd.in/gXZmHG8d #RareDiesease #HCWainwright